OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Kenneth F. Grossmann, Megan Othus, Sapna P. Patel, et al.
Cancer Discovery (2021) Vol. 12, Iss. 3, pp. 644-653
Open Access | Times Cited: 73
Kenneth F. Grossmann, Megan Othus, Sapna P. Patel, et al.
Cancer Discovery (2021) Vol. 12, Iss. 3, pp. 644-653
Open Access | Times Cited: 73
Showing 26-50 of 73 citing articles:
Challenges and opportunities of predicting overall survival benefit from improvements to recurrence-free survival in stage II/III melanoma: a correlation meta-analysis
LP Leung, John M. Kirkwood, S. Srinivasan, et al.
Immuno-Oncology Technology (2025) Vol. 25, pp. 101042-101042
Open Access
LP Leung, John M. Kirkwood, S. Srinivasan, et al.
Immuno-Oncology Technology (2025) Vol. 25, pp. 101042-101042
Open Access
Adjuvant Proton Beam Radiation Therapy for Sinonasal Mucosal Melanoma
Jamie Takayesu, Upendra Parvathaneni, George E. Laramore, et al.
Cancer Reports (2025) Vol. 8, Iss. 2
Open Access
Jamie Takayesu, Upendra Parvathaneni, George E. Laramore, et al.
Cancer Reports (2025) Vol. 8, Iss. 2
Open Access
Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028
Marco Donia, Henrik Jespersen, Mathilde Jalving, et al.
ESMO Open (2025) Vol. 10, Iss. 3, pp. 104295-104295
Closed Access
Marco Donia, Henrik Jespersen, Mathilde Jalving, et al.
ESMO Open (2025) Vol. 10, Iss. 3, pp. 104295-104295
Closed Access
Systemic Therapy for Melanoma
Ashlee Seldomridge, Roi Weiser, Ashley M. Holder
Surgical Oncology Clinics of North America (2025)
Closed Access
Ashlee Seldomridge, Roi Weiser, Ashley M. Holder
Surgical Oncology Clinics of North America (2025)
Closed Access
Pancreas-targeted lipid nanoparticles for relatively non-invasive interleukin-12 mRNA therapy in orthotopic pancreatic ductal adenocarcinoma
Qian Shen, Jia Liu, Ling Zeng, et al.
Journal of Controlled Release (2025) Vol. 381, pp. 113588-113588
Closed Access
Qian Shen, Jia Liu, Ling Zeng, et al.
Journal of Controlled Release (2025) Vol. 381, pp. 113588-113588
Closed Access
The Landmark Series: Melanoma and Adjuvant Therapy
Michael Lowe, Keith A. Delman, David W. Ollila
Annals of Surgical Oncology (2025)
Closed Access
Michael Lowe, Keith A. Delman, David W. Ollila
Annals of Surgical Oncology (2025)
Closed Access
Design considerations for randomized comparisons of neoadjuvant–adjuvant versus adjuvant-only cancer immunotherapy when tumor measurement schedules do not align (SWOG S1801)
Megan Othus, Elad Sharon, Michael C. Wu, et al.
Clinical Trials (2025)
Closed Access
Megan Othus, Elad Sharon, Michael C. Wu, et al.
Clinical Trials (2025)
Closed Access
Monoclonal antibodies as adjuvant therapies for resected melanoma
Islam Eljilany, Julita García, Basem T. Jamal, et al.
Expert Opinion on Biological Therapy (2025), pp. 1-14
Closed Access
Islam Eljilany, Julita García, Basem T. Jamal, et al.
Expert Opinion on Biological Therapy (2025), pp. 1-14
Closed Access
Adjuvant Anti–PD-1 Monotherapy Versus Observation for Stage III Acral Melanoma of the Sole: A Multicenter Retrospective Study in Japanese Patients
Shigeru Koizumi, Naoya Yamazaki, Yuki Ichigozaki, et al.
JCO Global Oncology (2025), Iss. 11
Open Access
Shigeru Koizumi, Naoya Yamazaki, Yuki Ichigozaki, et al.
JCO Global Oncology (2025), Iss. 11
Open Access
Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse
Ignacio Heras‐Murillo, Diego Mañanes, Pablo Munné, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Ignacio Heras‐Murillo, Diego Mañanes, Pablo Munné, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Robot-Assisted Pelvic Dissection for Enlarged Lymph Nodes in Melanoma Improves Recovery with Equivalent Oncological Outcomes to Open Pelvic Dissection
Amit Roshan, Bhumi Shah, Karen E. Anderson, et al.
Annals of Surgical Oncology (2024) Vol. 31, Iss. 4, pp. 2727-2736
Open Access | Times Cited: 3
Amit Roshan, Bhumi Shah, Karen E. Anderson, et al.
Annals of Surgical Oncology (2024) Vol. 31, Iss. 4, pp. 2727-2736
Open Access | Times Cited: 3
Immune Checkpoint Inhibitors in Geriatric Oncology
Sarah Cook, Md Al Amin, Shahla Bari, et al.
Current Oncology Reports (2024) Vol. 26, Iss. 5, pp. 562-572
Closed Access | Times Cited: 3
Sarah Cook, Md Al Amin, Shahla Bari, et al.
Current Oncology Reports (2024) Vol. 26, Iss. 5, pp. 562-572
Closed Access | Times Cited: 3
Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review
Islam Eljilany, Arish Noor, Mahati Paravathaneni, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2561-2561
Open Access | Times Cited: 8
Islam Eljilany, Arish Noor, Mahati Paravathaneni, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2561-2561
Open Access | Times Cited: 8
Comparison of efficacy and tolerability of adjuvant therapy for resected high-risk stage III-IV cutaneous melanoma: a systemic review and Bayesian network meta-analysis
He Ba, Fangyuan Zhu, Xiao-Ze Zhang, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 7
He Ba, Fangyuan Zhu, Xiao-Ze Zhang, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 7
The Effect of Sex on the Therapeutic Efficiency of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials
Xing‐Yu Zhong, Jian‐Xuan Sun, Na Zeng, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 382-382
Open Access | Times Cited: 2
Xing‐Yu Zhong, Jian‐Xuan Sun, Na Zeng, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 382-382
Open Access | Times Cited: 2
Avoiding Delays in Reporting Time-to-Event Randomized Trials: Calendar Backstops and Other Approaches
Megan Othus, Boris Freidlin, Edward L. Korn
Journal of Clinical Oncology (2024) Vol. 42, Iss. 31, pp. 3753-3760
Closed Access | Times Cited: 2
Megan Othus, Boris Freidlin, Edward L. Korn
Journal of Clinical Oncology (2024) Vol. 42, Iss. 31, pp. 3753-3760
Closed Access | Times Cited: 2
Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?
Sultana Mehbuba Hossain, Kevin Ly, Yih Jian Sung, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 10120-10120
Open Access | Times Cited: 2
Sultana Mehbuba Hossain, Kevin Ly, Yih Jian Sung, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 10120-10120
Open Access | Times Cited: 2
Braf-Mutant Melanomas: Biology and Therapy
Elvira Pelosi, Germana Castelli, Ugo Testa
Current Oncology (2024) Vol. 31, Iss. 12, pp. 7711-7737
Open Access | Times Cited: 2
Elvira Pelosi, Germana Castelli, Ugo Testa
Current Oncology (2024) Vol. 31, Iss. 12, pp. 7711-7737
Open Access | Times Cited: 2
Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials
Yuanfang Li, Shuqiang Yuan, Ying-Bo Chen, et al.
JNCI Journal of the National Cancer Institute (2023) Vol. 115, Iss. 9, pp. 1085-1091
Open Access | Times Cited: 6
Yuanfang Li, Shuqiang Yuan, Ying-Bo Chen, et al.
JNCI Journal of the National Cancer Institute (2023) Vol. 115, Iss. 9, pp. 1085-1091
Open Access | Times Cited: 6
Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field
Islam Eljilany, Ella Castellano, Ahmad A. Tarhini
Cancers (2023) Vol. 15, Iss. 16, pp. 4125-4125
Open Access | Times Cited: 6
Islam Eljilany, Ella Castellano, Ahmad A. Tarhini
Cancers (2023) Vol. 15, Iss. 16, pp. 4125-4125
Open Access | Times Cited: 6
Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma
Lotte Hoeijmakers, Irene L. M. Reijers, Christian U. Blank
Cancer Discovery (2023) Vol. 13, Iss. 11, pp. 2319-2338
Closed Access | Times Cited: 6
Lotte Hoeijmakers, Irene L. M. Reijers, Christian U. Blank
Cancer Discovery (2023) Vol. 13, Iss. 11, pp. 2319-2338
Closed Access | Times Cited: 6
Adjuvant PD-1 Blockade in Resected Melanoma: Is Preventing Recurrence Enough?
James W. Smithy, Alexander N. Shoushtari
Cancer Discovery (2022) Vol. 12, Iss. 3, pp. 599-601
Open Access | Times Cited: 7
James W. Smithy, Alexander N. Shoushtari
Cancer Discovery (2022) Vol. 12, Iss. 3, pp. 599-601
Open Access | Times Cited: 7
Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma
Ryan C. Augustin, Jason J. Luke
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 3, pp. 421-434
Closed Access | Times Cited: 1
Ryan C. Augustin, Jason J. Luke
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 3, pp. 421-434
Closed Access | Times Cited: 1
Treatment of Stage III Resectable Melanoma—Adjuvant and Neoadjuvant Approaches
Ahmad A. Tarhini, Ella Castellano, Islam Eljilany
The Cancer Journal (2024) Vol. 30, Iss. 2, pp. 54-70
Closed Access | Times Cited: 1
Ahmad A. Tarhini, Ella Castellano, Islam Eljilany
The Cancer Journal (2024) Vol. 30, Iss. 2, pp. 54-70
Closed Access | Times Cited: 1
Adjuvant PD-1 Checkpoint Inhibition in Early Cutaneous Melanoma: Immunological Mode of Action and the Role of Ultraviolet Radiation
Matthias Brandlmaier, Magdalena Hoellwerth, Peter Koelblinger, et al.
Cancers (2024) Vol. 16, Iss. 8, pp. 1461-1461
Open Access | Times Cited: 1
Matthias Brandlmaier, Magdalena Hoellwerth, Peter Koelblinger, et al.
Cancers (2024) Vol. 16, Iss. 8, pp. 1461-1461
Open Access | Times Cited: 1
